Olanzapine: A serotonin-dopamine-receptor antagonist for antipsychotic therapy

American Journal of Health-System Pharmacy

Volumn 55, Issue 10, 1998, Pages 1003-1016

  Bever, Kristine A ^a   Perry, Paul J ^b,c  

^a College of Medicine ^*

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

Antipsychotic agents; Contraindications; Costs; Dosage; Drug interactions; Olanzapine; Pharmacokinetics; Psychotic disorders; Schizophrenia; Toxicity

Indexed keywords

CLOZAPINE; DOPAMINE RECEPTOR BLOCKING AGENT; HALOPERIDOL; OLANZAPINE; RISPERIDONE; SEROTONIN ANTAGONIST; SERTINDOLE;

AGITATION; CLINICAL TRIAL; CONSTIPATION; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG LABELING; DRUG METABOLISM; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; INSOMNIA; OBSESSION; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SOMNOLENCE; XEROSTOMIA;

EID: 0032524493     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/55.10.1003     Document Type: Review

References (44)

1. Andreasen NC, Black DW. Introductory textbook of psychiatry. Washington, DC: American Psychiatric Press; 1995:203-28.
2. Pickar D. Prospects for pharmacotherapy of schizophrenia. Lancet. 1995; 345:557-62.
3. Meltzer HY. An overview of the mechanism of action of clozapine. J Clin Psychiatry. 1994; 55(suppl B):47-52.
4. Moore NA, Calligaro DO, Wong DT et al. The pharmacology of olanzapine and other new antipsychotic agents. Curr Opin Invest Drugs. 1993; 2:281-93.
5. Ereshefsky L, Watanabe MD, Tran-Johnson TK. Clozapine: an atypical antipsychotic agent. Clin Pharm. 1989; 8:691-709.
6. Borison RL. Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics. J Clin Psychopharmacol. 1995; 15(suppl 1):24S-9S.
7. Krupp P, Barnes P. Clozapine-associated agranulocytosis: risk and etiology. Br J Psychol. 1992; 160(suppl 17):38-41.
8. Zyprexa package insert. Indianapolis: Eli Lilly and Company; 1996 Nov.
9. Beasley CM, Tollefson G, Tran P et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 1996b; 14:111-23.
10. Stockton ME, Rasmussen K. Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neuropsychopharmacology. 1996; 14:97-104.
11. Obermeyer BD, Nyhart EH, Goodwin MR et al. The disposition of olanzapine (OL) in healthy volunteers. Pharmacologist. 1993; 35:253. Abstract.
12. Review and evaluation of clinical data. New drug application. Olanzapine application summary, Rockville, MD: Food and Drug Administration; 1996. [Obtained through the Freedom of Information Act.]
13. Ring BJ, Catlow J, Lindsay TJ et al. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther. 1996; 276:658-66.
14. Beasley CM, Sanger T, Satterlee W et al. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology. 1996a; 124:159-67.
15. Tollefson GD, Beasley CM, Tran PV et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychol. 1997; 154:457-65.
16. Tran PV, Hamilton SH, Kuntz AJ et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol. 1997; 17:407-18.
17. Overall JE. The Brief Psychiatric Rating Scale (BPRS): recent developments in ascertainment and scaling. Psychopharmacol Bull. 1988; 24:97-9.
18. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987; 13:261-76.
19. Andreasen NC. Negative symptoms in schizophrenia. Arch Gen Psychiatry. 1982; 39:784-8.
20. Perry PJ, Miller DD. Clinical use of clozapine plasma concentrations. In: Marder S, ed. Clinical use of neuroleptic plasma levels. 1st ed. Washington, DC: American Psychiatric Press; 1993.
21. Guy W. ECDEU assessment manual for psychopharmacology, revised version. Bethesda, MD: U.S. Department of Health, Education, and Welfare; 1976.
22. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970; 212:11-9.
23. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989; 154:672-6.
24. Taylor N, Beuzen JN, Wesnes K et al. The effect of olanzapine on cognition and psychomotor function in healthy elderly volunteers. Schizophr Res. 1996; 18:131. Abstract.
25. Baker RW, Ames D, Umbricht DG et al. Obsessive-compulsive symptoms in schizophrenia: a comparison of olanzapine and placebo. Psychopharmacol Bull. 1996; 32:89-93.
26. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, third edition - revised (DSM-III-R). Washington, DC: American Psychiatric Press; 1987.
27. Wolters EC, Jansen EH, Qua T et al. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology. 1996; 47:1085-7.
28. Chiu JA, Franklin RB. Analysis and pharmacokinetics of olanzapine (LY170053) and two metabolites in rat plasma using reversed-phase HPLC with electrochemical detection. J Pharm Biomed Anal. 1996; 14:609-15.
29. Catlow JT, Barton RD, Clemens M et al. Analysis of olanzapine in human plasma utilizing reversed-phase high-performance liquid chromatography with electrochemical detection. J Chromatogr. 1995; 668:85-90.
30. Perry PJ, Sanger T, Beasley C. Olanzapine plasma concentrations and clinical response in acutely ill schizophrenics. J Clin Psychopharmacol. 1997; 17:472-7.
31. Jibson MD, Tandon R. A summary of research findings on the new antipsychotic drugs. Psychol Forum. 1996; 16:1-7.
32. Street JS, Tamura R, Sanger T et al. Long-term treatment-emergent dyskinetic symptoms in patients treated with olanzapine and haloperidol. Psychopharmacol Bull. 1996; 32:522. Abstract.
33. Gonzalez FJ, Idle JR. Pharmacogenetic phenotyping and genotyping: present status and future potential. Clin Pharmacokinet. 1994; 26:59-70.
34. Harvey AT, Preskorn SH. Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part I. J Clin Psychopharmacol. 1996a; 16:273-85.
35. Harvey AT, Preskorn SH. Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part II. J Clin Psychopharmacol. 1996b; 16:345-55.
36. Preskorn SH. Reducing the risk of drug-drug interactions: a goal of rational drug development. J Clin Psychiatry. 1996; 57(suppl 1):3-6.
37. Slaughter RL, Edwards DJ. Recent advances: the cytochrome P450 enzymes. Ann Pharmacother. 1995; 29:619-24.
38. Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol. 1992; 22:1-21.
39. Ring BJ, Binkley SN, Vandenbranden M et al. In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A. Br J Clin Pharmacol. 1995; 41:181-6.
40. Muller-Oerlinghausen B, Demolle D, Onkelinx C et al. Pharmacokinetic interaction between olanzapine and lithium in healthy male volunteers. Pharmacopsychiatry. 1995; 28:201. Abstract.
41. Lieberman JA. Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. J Clin Psychiatry. 1996; 57(suppl 11):68-71.
42. Red book. Montvale, NJ: Medical Economics; 1997.
43. Glazer WM, Johnstone BM. Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia. J Clin Psychiatry. 1997; 58(suppl 10):50-4.
44. Perry PJ, Pursel M. Analysis of clozapine Medicaid cost data for fiscal year 1992-1993 for the State of Iowa. Des Moines, IA: Iowa Medicaid Drug Utilization Review Commission; 1995.